» Articles » PMID: 32460972

Timing of Primary Maternal Cytomegalovirus Infection and Rates of Vertical Transmission and Fetal Consequences

Overview
Publisher Elsevier
Date 2020 May 29
PMID 32460972
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Cytomegalovirus infection is the most frequent congenital infection and a major cause of long-term neurologic morbidity. The aim of this meta-analysis was to calculate the pooled rates of vertical transmission and fetal impairments according to the timing of primary maternal infection.

Data Sources: From inception to January 2020, MEDLINE, Scopus, Cochrane Library, and gray literature sources were used to search for related studies.

Study Eligibility Criteria: Cohort and observational studies reporting the timing of maternal cytomegalovirus infections and rate of vertical transmission or fetal impairments were included. The primary outcomes were vertical transmission and fetal insult, defined as either prenatal findings from the central nervous system leading to termination of pregnancy or the presence of neurologic symptoms at birth. The secondary outcomes included sensorineural hearing loss or neurodevelopmental delay at follow-up and prenatal central nervous system ultrasonography findings.

Study Appraisal And Synthesis Methods: The pooled rates of the outcomes of interest with their 95% confidence intervals (CI) were calculated for primary maternal infection at the preconception period, periconception period, first trimester, second trimester, and third trimester.

Results: A total of 17 studies were included. The pooled rates of vertical transmission (10 studies, 2942 fetuses) at the preconception period, periconception period, first trimester, second trimester, and third trimester were 5.5% (95% CI, 0.1-10.8), 21.0% (95% CI, 8.4-33.6), 36.8% (95% CI, 31.9-41.6), 40.3% (95% CI, 35.5-45.1), and 66.2% (95% CI, 58.2-74.1), respectively. The pooled rates of fetal insult in case of transmission (10 studies, 796 fetuses) were 28.8% (95% CI, 2.4-55.1), 19.3% (95% CI, 12.2-26.4), 0.9% (95% CI, 0-2.4%), and 0.4% (95% CI, 0-1.5), for maternal infection at the periconception period, first trimester, second trimester, and third trimester, respectively. The pooled rates of sensorineural hearing loss for maternal infection at the first, second, and third trimester were 22.8% (95% CI, 15.4-30.2), 0.1% (95% CI, 0-0.8), and 0% (95% CI, 0-0.1), respectively.

Conclusion: Vertical transmission after maternal primary cytomegalovirus infection increases with advancing pregnancy, starting from the preconception period. However, severe fetal impairments are rare after infection in the first trimester of pregnancy.

Citing Articles

The Angiogenic Markers PlGF and sFlt-1 in Cytomegalovirus Infection During Pregnancy: Insights from a Clinical Case.

Giardini V, Chiozzi R, Fernicola F, Casati M, Locatelli A, Ornaghi S Viruses. 2025; 17(2).

PMID: 40007022 PMC: 11860600. DOI: 10.3390/v17020267.


Proceedings of the Conference "CMV Vaccine Development-How Close Are We?" (27-28 September 2023).

Schleiss M, Crooks C, Karthigeyan K, Kruc R, Otero C, Wang H Vaccines (Basel). 2024; 12(11).

PMID: 39591134 PMC: 11598149. DOI: 10.3390/vaccines12111231.


Progress and Challenges in the Management of Congenital Cytomegalovirus Infection.

Szulc W, Szydlowska N, Smyk J, Majewska A Clin Pract. 2024; 14(6):2445-2462.

PMID: 39585019 PMC: 11587044. DOI: 10.3390/clinpract14060191.


Audiological and Vestibular Follow-Up for Children with Congenital Cytomegalovirus Infection: From Current Limitations to Future Directions.

Alde M, Fancello V, Di Mauro P, Canelli R, Zaouche S, Falanga C Children (Basel). 2024; 11(10).

PMID: 39457176 PMC: 11506510. DOI: 10.3390/children11101211.


Cytomegalovirus and pregnancy: current evidence for clinical practice.

Pontes K, Araujo Junior E Rev Assoc Med Bras (1992). 2024; 70(8):e20240509.

PMID: 39230148 PMC: 11370743. DOI: 10.1590/1806-9282.20240509.